Linked Data API

Show Search Form

Search Results

1702287
registered interest false more like this
date less than 2024-04-18more like thismore than 2024-04-18
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care remove filter
hansard heading Breastfeeding more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, whether she has made an assessment of the potential impact of increased rates of breastfeeding on cost savings for the NHS. more like this
tabling member constituency Gower more like this
tabling member printed
Tonia Antoniazzi more like this
uin 22611 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-04-25more like thismore than 2024-04-25
answer text <p>The public health benefits of breastfeeding for child and maternal health are significant and well established. Research published in the British Medical Journal suggests that increasing breastfeeding rates, both in terms of duration and exclusivity, is likely to generate substantial cost savings to the National Health Service, although the actual amounts saved will depend on the extent of this increase.</p><p>Through the Family Hubs and Start for Life Programme, we are investing £50 million to increase the range of specialist support, which is enabling more parents to access face-to-face and virtual support whenever they need it. One of the objectives of the programme is to improve the evidence base around the impact of breastfeeding interventions, and the specific combination of interventions that are effective in different circumstances. This is expected to strengthen the case for further, more widespread investment in the future.</p> more like this
answering member constituency South Northamptonshire more like this
answering member printed Andrea Leadsom more like this
question first answered
less than 2024-04-25T11:32:06.737Zmore like thismore than 2024-04-25T11:32:06.737Z
answering member
4117
label Biography information for Andrea Leadsom more like this
tabling member
4623
label Biography information for Tonia Antoniazzi remove filter
1689182
registered interest false more like this
date less than 2024-02-16more like thismore than 2024-02-16
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care remove filter
hansard heading Parkinson's Disease: Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, whether she is taking steps with the Medicines and Healthcare products Regulatory Agency to reduce the time taken to license (a) generic and (b) biosimilar medicines to treat Parkinson's disease. more like this
tabling member constituency Gower more like this
tabling member printed
Tonia Antoniazzi more like this
uin 14115 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-02-27more like thismore than 2024-02-27
answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) is taking urgent action to deliver improvements to decision timescales in established medicines, including those indicated to treat Parkinson’s disease. Last week we approved additional licences for this critical area. Whilst no specific discussions have taken place between the MHRA and my Rt hon. Friend, the Secretary of State for Health and Social Care on this matter, we are taking significant steps to assess applications for medicine approval within statutory timeframes and will always prioritise applications according to public health need.</p><p>We are working to reduce timelines by bringing in additional resources and developing processes that will result in significantly improved response times, while protecting patient safety. The measures we are putting in place are already resulting in significant improvements, and we will continue to publish monthly updates providing applicants with transparent information on expected timescales. As an effective regulator, we are committed to the highest of standards of performance and delivering the right outcomes for patients and public health.</p>
answering member constituency Pendle more like this
answering member printed Andrew Stephenson more like this
grouped question UIN 14114 more like this
question first answered
less than 2024-02-27T11:32:52.277Zmore like thisremove minimum value filter
answering member
4044
label Biography information for Andrew Stephenson more like this
tabling member
4623
label Biography information for Tonia Antoniazzi remove filter